Abstract
Chinese hamster ovary (CHO) cells have been used as the industry standard for the production of therapeutic monoclonal antibodies for several decades. Despite significant improvements in commercial-scale production processes and media, the CHO cell has remained largely unchanged. Due to the cost and complexity of whole-genome sequencing and gene-editing it has been difficult to obtain the tools necessary to improve the CHO cell line. With the advent of next-generation sequencing and the discovery of the CRISPR/Cas9 system it has become more cost effective to sequence and manipulate the CHO genome. Here, we provide a comprehensive de novo assembly and annotation of the CHO-K1 based CHOZN® GS−/− genome. Using this platform, we designed, built, and confirmed the functionality of a whole genome CRISPR guide RNA library that will allow the bioprocessing community to design a more robust CHO cell line leading to the production of life saving medications in a more cost-effective manner.
Author supplied keywords
Cite
CITATION STYLE
Kretzmer, C., Narasimhan, R. L., Lal, R. D., Balassi, V., Ravellette, J., Kotekar Manjunath, A. K., … Razafsky, D. (2022). De novo assembly and annotation of the CHOZN® GS−/− genome supports high-throughput genome-scale screening. Biotechnology and Bioengineering, 119(12), 3632–3646. https://doi.org/10.1002/bit.28226
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.